One of the largest risks associated with using Zepbound is the development of gastroparesis, also known as delayed gastric emptying or stomach paralysis
[DOI] [PMC free article] [PubMed] [Google Scholar] 211.Wang YY, Attane C, Milhas D, Dirat B, Dauvillier S, Guerard A, et al
Building muscle while on a GLP-1 is possible, but it is significantly harder than in a calorie-neutral or calorie-surplus state
doi: 10.1007/S11154-014-9289-5 27 KalinderiKPapaliagkasVFidaniL
The program covers three FDA-approved GLP-1 weight-loss medications through a centralized Medicare process separate from standard Part D drug coverage: Wegovy (injectable and tablet formulations) Zepbound (KwikPen only) Foundayo (oral formulation) To be eligible, patients must be enrolled in a Medicare Part D plan and meet BMI and health criteria
In addition to its agreement with Hims & Hers, Novo also signed deals this week with two other telehealth providers for discounted Wegovy Ro and LifeMD